Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE5026 dose-response study for venous thromboembolism prevention after total knee replacement
2005-006202-26Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semuloparin in venous thromboembolism (VTE) (5 arms), sponsored by Sanofi. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Mar 2006; status: completed.
02
Drugs
semuloparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2005-006202-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006202-26.